Don't Miss These 5 Earnings Charts

This is the busiest week of earnings season with over 1000 companies reporting including many big cap glamour names.

But what about the other companies that fewer follow?

These 5 companies each have intriguing earnings charts. One company is in a recovering industry, another was the hottest IPO of 2018 and a third is in one of the hottest industries of the year: insurance.

Can these companies surprise again with all eyes on them?

5 Earnings Charts You Shouldn’t Miss

1. 1. Allstate (NYSE:ALL) has one of the best charts this week with just one miss in the last 5 years. Shares are up 78% over the last 5 years, beating the 51% return of the S&P 500. Is this a hidden investing gem?

2. 2. CF Industries (NYSE:CF) has already seen its shares bounce off of its cycle lows. Fertilizer prices had been in the decline for several years but now they’re on the move higher. The industry expects low supply and strong demand for the foreseeable future. Will CF report spectacular results this quarter?

3. 3. Fitbit (NYSE:FIT) was a glamour stock until it wasn’t. However, it has put together 5 beats in a row but Wall Street isn’t rewarding it as the shares remain depressed. Will this be the quarter when they finally break out?

4. 4. Spotify (NYSE:SPOT) was the hottest IPO of 2018 but the shares have really taken a beating in the sell off. They’re down 16% in the last month. It has missed once and beat once. Can it get back on track this quarter?

5. Wayfair (NYSE:W) is in an intense competition with Amazon (NASDAQ:AMZN) and other low-cost home accessory companies. The stock has sold off recently on worries about growth, falling 22% in the last 4 weeks. Are these shares coming back down to earth or is this pullback just temporary?

3 Medical Stocks to Buy Now

The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.

So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.

See them today for free >>